Conditions: Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 29
Healthy volunteers: yes

Brief summary:
This is a phase I study of LY3031207 in healthy subjects. The purposes of this study are to look at safety, how well the study drug is tolerated, and how much of the study drug gets into the blood stream and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Subjects will participate in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.

Detailed description:

Arms:
arm 1: Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally. arm 2: Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose. arm 3: Single 400mg dose of celecoxib administered orally on one occasion.

Interventions: intervention 1: LY3031207 intervention 2: Placebo intervention 3: Celecoxib
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered orally

Protocol document: